The recent news relating to Laboratory Corporation of America Holdings LH has seen a variety of asset management firms altering their stakes in the company. Some, such as Assenagon Asset Management, are decreasing their holdings, while others, like Wedge Capital Management, Swiss Life Asset Management and Gotham Asset Management, increase their stocks. Labcorp has also recently secured a new $750 million term loan and appointed Victor Bulto to its Board of Directors. Morgan Stanley has increased their price target for Labcorp's shares and maintained their 'Overweight' rating.
The company's recent dividend announcement($0.72) as well as its strategic alliance with Illumina has led to an enhanced focus on precision oncology. The earnings outlook for Labcorp has been updated. Labcorp's acquisition of select assets of BioReference Health's Innovative Oncology and related Clinical Testing Services Businesses is an important move, and they have also highlighted ambitious revenue growth plans for FY26. The firm's quarterly financial results have generally surpassed estimates. The investment narrative for Labcorp is being reframed with a focus on oncology innovation.
Laboratory Corporation of America Holdings LH News Analytics from Wed, 05 Nov 2014 08:00:00 GMT to Wed, 01 Apr 2026 07:23:04 GMT - Rating 7 - Innovation 2 - Information 6 - Rumor -3
